Bayer-Vitiva partnership
This article was originally published in The Tan Sheet
Executive Summary
Bayer Pharmaceuticals and Vitiva have signed an agreement to develop exclusive isolation of esters from marigold flowers, the firms announce July 5. The initiatve is related to Bayer's registered patent for a natural OTC product based on marigold flower extract, a press release adds. The partnership will "stimulate development of innovative products and will deliver new solutions for consumers who prefer to use natural ingredients," Vitiva says. Bayer Pharmaceuticals is part of the new Global Pharmaceutical Division that was established Jan. 1 and grew out of the former Biological Products and Pharmaceutical Division...
You may also be interested in...
UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
EU ‘Structured Dialog’ Offers Opportunity To Secure Supply
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.
Adcock Struggles As South African Healthcare Awaits Relief
Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: